GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Riociguat (Adempas), oral tablets for pulmonary hypertension

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Adempas - labeled renal guidance

Product / population
Riociguat (Adempas), oral tablets for pulmonary hypertension
Renal method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
DailyMed SPL version 32, effective 2026-08-13; posted Aug 19, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Adempas - product and source limitations

Safety and efficacy are unestablished in these populations. The label gives no renal starting dose or dialysis supplement.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Adempas - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Riociguat (Adempas), oral tablets for pulmonary hypertension

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date: DailyMed SPL version 32, effective 2026-08-13; posted Aug 19, 2026
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Highlights, Use in Specific Populations; section 8.6

Use is not recommended for patients on dialysis or with CrCl below 15 mL/min. Safety and efficacy are unestablished in these populations. The label gives no renal starting dose or dialysis supplement.

RDM73-adempas-official-1 · Source locator: Renal guidance: Highlights, Use in Specific Populations; section 8.6

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b57509a-3d5d-41d4-8fed-1471e26372a3
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date/version
DailyMed SPL version 32, effective 2026-08-13; posted Aug 19, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
e6d66869ddfa804dc99ffd371daebbb1b2c9f5ef2390e069fa75df35fdc0b829

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=riociguat-adempas&s1=RDM73-adempas-official&h1=df6c0b1ee9ad593b0c8d11a8fa7156bf277db991dee4fea2dd6bd3db76c49333

Top